At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 903 enrolled
Drug / intervention
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitordrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb, Randomized, Parallel Group, Double-Blind, Double-Dummy, Multi-Center, Multi-National, Multi-Dose, Study of DU-176b Compared to Dalteparin in Patients Undergoing Elective Unilateral Total Hip Replacement
In Brief
A Phase 2 clinical trial evaluating DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor for Thrombosis and Hip Replacement. Completed, enrolled 903 participants across 29 sites in 7 countries.
Detailed Summary
This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThrombosis, Hip Replacement
CountriesCanada, Denmark, Hungary, Latvia, Russia, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedNov 2006
Primary CompletionJun 2007
TodayJul 2026
First PostedNov 10, 2006
Enrollment StartMay 1, 2006
Primary CompletionJun 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 19.6 years ago
Interventions
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitordrug